Trial confirms excess cancer risk with tofacitinib
A safety trial was mandated after clinicians noted an increased incidence among patients
Use of tofacitinib for rheumatoid arthritis increases the risk of developing cancer by almost 50% compared with therapy with a TNF inhibitor, according to a US safety analysis.
The findings have already prompted the Food and Drug Administration to add a ‘black box’ warning on tofacitinib, as well as two other Janus kinase (JAK) inhibitors.
